在高效抗逆转录病毒治疗（HAART）时代之前，对晚期HIV-1感染患者进行治疗性疫苗接种（p24病毒样颗粒）不会改变CD4细胞数量的下降。

Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline.

作者信息

Smith D, Gow I, Colebunders R, Weller I, Tchamouroff S, Weber J, Boag F, Hales G, Adams S, Patou G, Cooper D A

机构信息

National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia.

出版信息

HIV Med. 2001 Oct;2(4):272-5. doi: 10.1046/j.1468-1293.2001.00080.x.

DOI:10.1046/j.1468-1293.2001.00080.x

PMID:11737409

Abstract

In a randomized placebo controlled trial 304 HIV infected patients with CD4 cell counts below 350 cells/microL received therapeutic vaccination with: alum placebo (Group I, n = 102), p24-VLP 500 microg (Group II, n = 101) or p24-VLP 1000 microg (Group III, n = 101) p24-VLP monthly for six months. Over one year the average change in CD4 cell count did not differ significantly between groups (-32, -40 and -52 cells per microL respectively). There was also no difference between groups in progression to CDC category B or C events, or in adverse events. Therapeutic vaccination with p24-VLP does not affect CD4 cell decline in patients with advanced HIV infection.

摘要

在一项随机安慰剂对照试验中，304名CD4细胞计数低于350个/微升的HIV感染患者接受了如下治疗性疫苗接种：明矾安慰剂（第一组，n = 102）、500微克p24病毒样颗粒（第二组，n = 101）或1000微克p24病毒样颗粒（第三组，n = 101），每月接种p24病毒样颗粒，共六个月。在一年多的时间里，各组之间CD4细胞计数的平均变化无显著差异（分别为每微升-32、-40和-52个细胞）。在进展为美国疾病控制与预防中心（CDC）B类或C类事件方面，以及在不良事件方面，各组之间也没有差异。用p24病毒样颗粒进行治疗性疫苗接种不会影响晚期HIV感染患者CD4细胞的减少。